The clinical study of primary gout and comparative evaluation of Habb-E-Suranjan with allopurinol in its management

Abstract

Gout (Niqras) involves many aspects of a person’s life and increasing prevalence placing a huge burden on Nations health. The study aim was to assess the efficacy and safety of Unani pharmacopoeial formulation Habb-e-Suranjan on primary gouty patients. This was an 18 months, randomized open with Standard control study, carried out on 60 patients (30 Test group+30 Control group) and improvements in subjective parameters were assessed weekly and in objective parameter at the baseline, 15 days and 30 days. The subjective parameters were graded arbitrarily from 0- 3 according to severity in both group. There was a significant improvement in subjective and objective parameters in both groups and no adverse effects were observed during and after trial. Thus, it can be concluded that Habb-e-suranjan and Allopurinol both were significantly effective in resolving the symptoms and signs of gouty arthritis and both have significant effect on reducing serum uric acid level.